159 related articles for article (PubMed ID: 35847924)
1. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():883399. PubMed ID: 35847924
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
[TBL] [Abstract][Full Text] [Related]
6. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
Thirasastr P; Somaiah N
Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
[TBL] [Abstract][Full Text] [Related]
7. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
Liu B; Kou Y
J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
[TBL] [Abstract][Full Text] [Related]
8. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
9. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
[TBL] [Abstract][Full Text] [Related]
10. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
[TBL] [Abstract][Full Text] [Related]
13. Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NSM; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():1028118. PubMed ID: 36313668
[TBL] [Abstract][Full Text] [Related]
14. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
Zhang Y; Huang Z
Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
[No Abstract] [Full Text] [Related]
15. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J
Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M
BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
Lim SY; Ferro-López L; Barquin E; Lindsay D; Thway K; Smith MJ; Benson C; Jones RL; Napolitano A
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473346
[TBL] [Abstract][Full Text] [Related]
18. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
19. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
Symcox M; Somaiah N
Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
[TBL] [Abstract][Full Text] [Related]
20. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Kurokawa Y; Honma Y; Sawaki A; Naito Y; Iwagami S; Komatsu Y; Takahashi T; Nishida T; Doi T
Ann Oncol; 2022 Sep; 33(9):959-967. PubMed ID: 35688358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
